This milestone represents a solid step forward in the clinical development of IMC-003, laying a crucial foundation for evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics under multiple dosing regimens, and holding promise to bring new hope to patients suffering from PAH.